EUVIMEDDescoperă EUVIMED
VergleichsstudieBeobachtungsstudieOpen access · CC BY-NC 4.0

Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation

Lucie Simonis iD, Lorenz Balcar iD, Anna Schedlbauer, Marta Tonon, Nikolaj Torp iD, Valeria Santori, Katharina Stopfer, Jan Embacher, Christian Sebesta iD, Leonie Hafner, Benedikt Silvester Hofer iD, Nina Dominik iD and 8 more

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70302 ↗

At a glance

Vergleichsstudie in Alimentary Pharmacology & Therapeutics, 2025. Written by Lucie Simonis and 19 co-authors. Institution: Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. Major MEDLINE topics: Liver Cirrhosis, Ascites, Liver. Cited 4 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY-NC 4.0).

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Background

A more granular understanding of hepatic decompensation in cirrhosis has led to the classification of acute decompensation (AD) and non‐acute decompensation (NAD). In this study, we assessed differences in the clinical course of AD versus NAD in patients with ascites as the first decompensation event.

Methods

505 cirrhosis patients with ascites as first decompensation were included in this single‐center longitudinal cohort study and followed until further decompensation, orthotopic liver transplantation (OLT), or death. AD was defined as grade 3 ascites or ascites with spontaneous bacterial peritonitis (SBP) or acute‐kidney injury (AKI), while NAD was defined as grade 2 ascites. Hospitalisation was recorded.

Results

Among 505 patients, 296 (58.6%) met the criteria for AD, with 216 (73.0%) requiring hospitalisation. NAD occurred in 209 (41.4%), with 107 (51.2%) requiring hospitalisation. During a median 4.4‐year follow‐up, further decompensation occurred in 65.1%, acute‐on‐chronic liver failure (ACLF) in 27.7%, 10.9% underwent OLT, and 51.1% died. Patients with AD had a higher incidence of further decompensation (at 12 months: 19% and 33%) and a higher risk of transplant‐free mortality (subdistribution hazard ratio [SHR]: 1.43 [95% CI: 1.12–1.82], p = 0.004) versus NAD. When stratified by hospitalisation, AD was associated with an increased risk of mortality only in cases requiring hospitalisation (SHR for hospitalised AD vs. non‐hospitalised NAD: 1.89, 95% CI: 1.35–2.65, p < 0.001). Inflammation (C‐reactive protein) predicted transplant‐free mortality in AD (SHR per log‐change: 1.20 [95% CI: 1.02–1.41], p = 0.032) but not NAD.

Conclusions

Classifying patients as AD versus NAD identified subgroups with different risks for further decompensation and transplant‐free mortality.

Subjects

MeSH terms (MEDLINE)

Liver CirrhosisAscitesLiverPrognosisAcute DiseaseLongitudinal StudiesPeritonitisAcute Kidney InjuryFollow-Up StudiesHospitalizationLiver TransplantationRisk FactorsHumansMaleFemaleAdultMiddle AgedAged

Author keywords

acute decompensationascitescirrhosishepatic decompensationnon‐acute decompensation

Authors and institutions

  • Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Unit of Internal Medicine and Hepatology, Department of Medicine, University of Padova, Padova, Italy.
  • Centre for Liver Research, Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark.
  • Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.

ORCID profiles: Lucie Simonis, Lorenz Balcar, Nikolaj Torp, Christian Sebesta, Benedikt Silvester Hofer, Nina Dominik, Georg Kramer, Aleksander Krag, Mattias Mandorfer, Thomas Reiberger, Georg Semmler

Cite

APA

Simonis, L., Balcar, L., Schedlbauer, A., Tonon, M., Torp, N., Santori, V., Stopfer, K., Embacher, J., Sebesta, C., Hafner, L., Hofer, B. S., Dominik, N., Kramer, G., Thöne, P., Trauner, M., Krag, A., Piano, S., Mandorfer, M., Reiberger, T., & Semmler, G. (2025). Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70302

Vancouver

Simonis L, Balcar L, Schedlbauer A, Tonon M, Torp N, Santori V, et al. Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70302

BibTeX
@article{Simonis2025,
  author = {Simonis, Lucie and Balcar, Lorenz and Schedlbauer, Anna and Tonon, Marta and Torp, Nikolaj and Santori, Valeria and Stopfer, Katharina and Embacher, Jan and Sebesta, Christian and Hafner, Leonie and Hofer, Benedikt Silvester and Dominik, Nina and Kramer, Georg and Thöne, Paul and Trauner, Michael and Krag, Aleksander and Piano, Salvatore and Mandorfer, Mattias and Reiberger, Thomas and Semmler, Georg},
  title = {Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70302}
}
Start for free →